75 related articles for article (PubMed ID: 2978521)
1. Fatal pulmonary embolus in a patient treated with Marvelon.
Scolding NJ; Gibby OM
J R Coll Gen Pract; 1988 Dec; 38(317):568. PubMed ID: 2978521
[No Abstract] [Full Text] [Related]
2. Comments on desogestrel and gestoden (3rd generation progestogens) and the incidence of thromboembolism.
Lauritzen C
Horm Metab Res; 1996 May; 28(5):245-7. PubMed ID: 8738115
[No Abstract] [Full Text] [Related]
3. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles].
Bilotta P; Favilli S
Minerva Ginecol; 1987 Dec; 39(12):855-69. PubMed ID: 3329705
[No Abstract] [Full Text] [Related]
4. Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance.
Rákóczi I; Gerö G; Demeter J; Gáti I
Arzneimittelforschung; 1985; 35(3):630-3. PubMed ID: 3158320
[TBL] [Abstract][Full Text] [Related]
5. Marvelon--an OC with a new progestagen.
Drug Ther Bull; 1984 Sep; 22(18):69-70. PubMed ID: 6236963
[No Abstract] [Full Text] [Related]
6. Safety of combined oral contraceptive pills.
Cramer DW
Lancet; 1996 Feb; 347(9000):546-8. PubMed ID: 8596297
[No Abstract] [Full Text] [Related]
7. Safety of modern oral contraceptives.
Henzl MR
Lancet; 1996 Jan; 347(8996):257-8. PubMed ID: 8551892
[No Abstract] [Full Text] [Related]
8. Third generation oral contraceptives.
Skegg DC
BMJ; 2000 Jul; 321(7255):190-1. PubMed ID: 10903631
[No Abstract] [Full Text] [Related]
9. Third generation oral contraceptives containing desogestrel and gestodene and the risk of thrombosis.
Griffin JP
Adverse Drug React Toxicol Rev; 1996 Mar; 15(1):5-7. PubMed ID: 8920631
[No Abstract] [Full Text] [Related]
10. [Hormonal contraception with marvelon. Experiences with marvelon in gynecologic practice--a multicenter study by 265 gynecologists on over 26,000 women].
Geissler KH
Fortschr Med; 1983 Jun; 101(22):1060-4. PubMed ID: 6223870
[No Abstract] [Full Text] [Related]
11. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Meurer LN; Slawson JG
J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
[No Abstract] [Full Text] [Related]
12. Safety of modern oral contraceptives. The International Committee for Research in Reproduction.
Johannisson E
Lancet; 1996 Jan; 347(8996):258. PubMed ID: 8551893
[No Abstract] [Full Text] [Related]
13. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W
Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800
[TBL] [Abstract][Full Text] [Related]
14. [Thromboembolism and synthetic estroprogestational hormones. Apropos of 2 cases].
Boespflug O
Phlebologie; 1975; 28(3-4):373-4. PubMed ID: 1230800
[No Abstract] [Full Text] [Related]
15. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
[TBL] [Abstract][Full Text] [Related]
16. [The new low-dose contraceptive Logest--first impressions].
Sirakov M
Akush Ginekol (Sofiia); 2000; 39 Suppl 1():19-20. PubMed ID: 10948638
[No Abstract] [Full Text] [Related]
17. [Marvelon. A contraceptive pill with desogestrel, a new gestagenic substance].
Felding IC; Mikkelsen AL
Ugeskr Laeger; 1985 Oct; 147(42):3330-2. PubMed ID: 2934882
[No Abstract] [Full Text] [Related]
18. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
19. [Marvelon--when adverse effects became marketing arguments].
Fjoerestad I
Tidsskr Nor Laegeforen; 1986 Aug; 106(22):1735-8. PubMed ID: 2946094
[No Abstract] [Full Text] [Related]
20. [Marvelon--when adverse effects become marketing arguments].
Fjaerestad I
Tidsskr Nor Laegeforen; 1986 Aug; 106(23):1865-6. PubMed ID: 2945284
[No Abstract] [Full Text] [Related]
[Next] [New Search]
